IonQ (IONQ) valuation
TrendArc score 28 of 100 · Health 2.2 · Momentum 0.1 · Moat 4.4 · scored Nov 17, 2026 · How the score works
IonQ P/E ratio history
As of November 17, 2026, IonQ trades at 26.4 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $44.87 | -$1.82 | n/m |
| Dec 31, 2024 | $41.77 | -$1.56 | n/m |
| Dec 31, 2023 | $12.39 | -$0.78 | n/m |
| Dec 31, 2022 | $3.45 | -$0.25 | n/m |
| Dec 31, 2021 | $16.70 | -$0.76 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
IonQ valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| IonQIONQ | $9.46B | 26.4 | — | 24.9 |
| NovaNVMI | $9.81B | 35.3 | 23.5 | 9.8 |
| Skyworks SolutionsSWKS | $12.9B | 75.4 | 15.0 | 3.3 |
| First SolarFSLR | $16.4B | 8.9 | 7.0 | 3.3 |
| CamtekCAMT | $4.43B | 35.8 | 20.0 | 8.1 |
| Credo TechnologyCRDO | $23.1B | 43.6 | 17.3 | 14.5 |
| Qnity ElectronicsQ | $24.0B | 43.2 | 19.9 | 4.4 |
| Cerebras SystemsCBRS | $24.7B | — | — | — |
| ON SemiconductorON | $26.4B | 40.7 | 15.5 | 4.2 |
| Peer median | 40.7 | 17.3 | 4.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: IONQ financials · IONQ returns
No forecast, no recommendation. This page describes IonQ from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.
The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.